Wenxue Ma, Executive Guest Editor at Cytokine and Growth Factor Reviews, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“A commentary entitled “CD47-targeted therapy in cancer immunotherapy: at a crossroads of promise and challenge” is now available online.
Despite a strong biological rationale, the first-generation CD47 inhibitors encountered clinical roadblocks such as anemia, limited selectivity, and modest single-agent efficacy, leading several programs to pause or terminate.
These setbacks don’t mark the end rather, they underscore the importance of precision engineering, biomarker-guided patient selection, and rational combination strategies to fully realize the therapeutic potential of CD47 blockade.”
Title: CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge
Authors: Xuejun Guo, Yilin Fu, Natalia Baran, Wenxue Ma
Read the Full Article on Oncology Research
Natalia Baran, Adjunct Assistant Professor at The University of South Dakota, Sanford School of Medicine, shared this post, adding:
“Thrilled to be part of this commentary, where we explore the rise and recent setbacks of CD47-targeted therapies in cancer.
We highlight innovative strategies: like SIRPα agents and biomarker-driven approaches, that could redefine cancer immunotherapy with safer, more precise solutions.
Thank you Prof. Wenxue Ma for inviting me to this initiative!”
More posts featuring Wenxue Ma.